How to Get Oral Micronized Progesterone in Florida

Why Oral Micronized Progesterone Matters for HRT

Progesterone's primary role in hormone replacement therapy is preventing estrogen-driven endometrial hyperplasia. Without it, unopposed estrogen raises endometrial cancer risk by a factor of 2 to 10 depending on dose and duration, according to the Endocrine Society's 2015 clinical practice guideline. Oral micronized progesterone (OMP) is the bioidentical formulation the FDA approved in 1998 under the brand name Prometrium.

The PEPI trial (N=875) established that OMP paired with conjugated equine estrogen protected the endometrium as effectively as medroxyprogesterone acetate (MPA) while producing a more favorable lipid profile. HDL cholesterol rose 4.1 mg/dL in the OMP arm versus a 2.4 mg/dL decline with MPA. That lipid advantage is one reason prescribers increasingly favor OMP over synthetic progestins.

For Florida residents starting or continuing HRT, access depends on three things: a licensed prescriber, a dispensing pharmacy, and a payment pathway. Each step has state-specific details worth knowing before your first appointment.

Who Can Prescribe OMP in Florida

Florida law permits four provider types to prescribe oral micronized progesterone: physicians (MD/DO), physician assistants (PA), and advanced registered nurse practitioners (ARNP). PAs and ARNPs prescribe under supervisory protocols defined by Florida Statute 464.012 and 458.347, respectively, though HRT prescribing falls within general scope for all four categories.

A 2023 workforce analysis from the Florida Department of Health counted over 72,000 actively licensed physicians and more than 38,000 ARNPs statewide. Practically, that means most women in urban and suburban Florida can find a local prescriber without difficulty. Rural counties may have fewer options, which is where telehealth fills the gap.

Board-certified endocrinologists and OB-GYNs are the most common prescribers for HRT-related progesterone. But family medicine physicians and internists routinely prescribe it, too. The 2022 Hormone Therapy Position Statement from the North American Menopause Society (NAMS) confirms that any trained clinician can manage standard menopausal HRT, including progesterone prescribing.

Telehealth Prescribing in Florida

Florida explicitly authorizes telehealth prescribing of non-controlled medications under FL Statute 456.47. OMP is not a controlled substance, so it qualifies for a fully remote initial consultation. No in-person visit is required before the first prescription.

Here is what a typical telehealth visit looks like in practice. You complete an intake form covering menstrual history, current symptoms, surgical history (specifically whether the uterus is intact), and any prior hormone use. The provider reviews recent labs or orders new ones. If you meet prescribing criteria, the clinician sends an electronic prescription to your pharmacy the same day.

Florida's telehealth statute requires the prescriber to hold an active Florida medical license. Out-of-state providers cannot prescribe to a Florida address unless they also carry a Florida license. This rule applies to national telehealth platforms as well: the clinician on your video call must be Florida-licensed, even if the company is headquartered elsewhere.

Visit duration typically runs 15 to 30 minutes. Turnaround from consultation to e-prescription is often same-day, though some platforms batch prescriptions within 24 to 48 hours.

Labs Required Before Starting Progesterone

A baseline lab panel is standard before initiating OMP, though no Florida-specific regulation mandates specific tests. Most prescribers follow the Endocrine Society and NAMS guidelines and order the following:

Core panel:

• Serum progesterone
• Estradiol (E2)
• Follicle-stimulating hormone (FSH)
• Complete metabolic panel (CMP) including liver enzymes (AST/ALT)
• Lipid panel
• CBC

Conditional add-ons depending on history:

• Thyroid panel (TSH, free T4) if fatigue or weight changes are present
• Hemoglobin A1c if metabolic risk factors exist
• Endometrial thickness via transvaginal ultrasound if abnormal bleeding is reported

Liver function testing matters here because OMP undergoes first-pass hepatic metabolism. The FDA-approved Prometrium label lists active liver disease and unexplained vaginal bleeding as contraindications. Prescribers will not initiate OMP without confirmed normal hepatic function.

Labs can be drawn at any Quest, Labcorp, or hospital-affiliated draw site across Florida. Many telehealth providers send a lab requisition to your preferred location. Results are usually available within 2 to 4 business days.

Pharmacy Options: Retail vs. 503A Compounding

Florida residents fill OMP prescriptions through two pathways: retail pharmacies and 503A compounding pharmacies.

Retail (brand or generic)

Generic micronized progesterone capsules (100 mg and 200 mg) are stocked at CVS, Walgreens, Publix, and Walmart locations throughout Florida. Brand-name Prometrium, originally manufactured by Solvay (now AbbVie), is also available but costs significantly more. A 30-day supply of generic 200 mg capsules typically runs $15 to $45 with a GoodRx-type discount, while brand Prometrium may exceed $200 without insurance.

The FDA's Orange Book lists multiple approved generics with an AB therapeutic equivalence rating, meaning they are considered interchangeable with Prometrium at the pharmacy counter.

503A Compounding

Florida's Board of Pharmacy licenses 503A compounding pharmacies under Chapter 465, Florida Statutes. These pharmacies can prepare custom progesterone formulations, including non-standard doses (e.g., 150 mg capsules), combination capsules with estradiol, or progesterone in peanut-oil-free bases for patients with allergies. Prometrium's commercial formulation contains peanut oil, which is a genuine allergen concern for a subset of patients.

503A pharmacies in Florida must dispense pursuant to a valid patient-specific prescription. They cannot ship across state lines under federal law (that requires 503B outsourcing facility registration). Florida-based patients receiving compounded progesterone must use a Florida-licensed 503A pharmacy.

Insurance Coverage and Cost in Florida

Insurance coverage for OMP in Florida breaks down along three lines.

Commercial insurance: Most employer-sponsored and ACA marketplace plans cover generic micronized progesterone with a Tier 1 or Tier 2 copay, typically $5 to $30 per month. Brand-name Prometrium often sits on Tier 3 or requires prior authorization. A Kaiser Family Foundation analysis of 2024 formulary data found that 89% of commercial plans included at least one generic progesterone product without step therapy.

Florida Medicaid: Florida's Medicaid program does not cover oral micronized progesterone for the HRT indication of endometrial protection. Coverage is limited to progesterone prescribed for type 2 diabetes-related indications. Women on Florida Medicaid who need OMP for HRT will likely need to pay out of pocket or explore patient assistance programs.

Medicare Part D: Most Part D plans cover generic progesterone capsules. Enrollees should verify formulary placement during open enrollment, as tier assignments shift annually.

For uninsured or underinsured patients, manufacturer discount programs and pharmacy discount cards bring the generic cost to roughly $12 to $25 for a 30-day supply. The out-of-pocket ceiling is low enough that cost rarely blocks access for this specific medication.

Prior Authorization: When It Applies and What You Need

Prior authorization for OMP in Florida is uncommon for the generic formulation but may be required for brand Prometrium or for doses exceeding standard guidelines. When it does apply, the insurer typically requests:

1. Documentation of an intact uterus (since progesterone is indicated only for women with a uterus on estrogen therapy)
2. Confirmation of concurrent estrogen prescription
3. Lab results showing menopausal or perimenopausal hormone levels (elevated FSH, low estradiol)
4. A letter of medical necessity if the brand is requested over the generic

The prescriber's office handles the prior authorization submission. Approval timelines in Florida average 3 to 5 business days, though urgent or expedited requests can be processed in 24 to 72 hours under Florida Insurance Code 627.42392.

If a prior authorization is denied, Florida law grants a right to appeal. The appeal must include clinical rationale, often citing the PEPI trial data or NAMS guidelines to demonstrate medical necessity.

Transferring a Progesterone Prescription to Florida

Prescription transfers are routine for OMP. If you already have an active prescription from another state, your Florida pharmacist can process a transfer by contacting the originating pharmacy directly. Florida does not impose additional restrictions on transferring non-controlled prescriptions.

There is one caveat. If the original prescription was for a compounded formulation from a 503A pharmacy in another state, the receiving Florida 503A pharmacy must prepare the compound fresh under their own license. They cannot simply dispense a product compounded elsewhere. A new prescription from a Florida-licensed provider may be cleaner in this scenario than attempting a transfer.

Standard retail-to-retail transfers (e.g., Walgreens in Georgia to Walgreens in Florida) usually complete within one business day.

Dosing Protocols: Cyclic vs. Continuous

Prescribers in Florida follow the same evidence-based dosing protocols used nationally. Two regimens predominate.

Cyclic dosing: 200 mg taken orally at bedtime for 12 to 14 days of each 28-day cycle. This approach mimics the luteal phase and produces a predictable withdrawal bleed. The PEPI trial used this protocol and confirmed endometrial protection equivalent to MPA at the 200 mg cyclic dose [1].

Continuous dosing: 100 mg taken orally every night without interruption. This is preferred by women who want to avoid monthly bleeding. A 2007 study in Climacteric (N=291) found that continuous 100 mg OMP provided adequate endometrial suppression in postmenopausal women using transdermal estradiol, with amenorrhea rates exceeding 80% at 12 months.

Both regimens are taken at bedtime because OMP has sedative properties mediated by its metabolite allopregnanolone, a GABA-A receptor modulator. This side effect is dose-dependent and actually beneficial for women with menopause-related insomnia. The FDA label specifically recommends evening dosing to minimize daytime drowsiness.

OMP capsules should be taken with food to enhance absorption. A pharmacokinetic study published in Fertility and Sterility showed that a high-fat meal increased progesterone bioavailability by 25 to 45% compared to fasting administration.

Timeline: Consultation to Medication

The end-to-end timeline for a Florida resident starting OMP through telehealth typically looks like this:

• Day 1: Schedule telehealth consultation and complete intake forms
• Day 2 to 3: Lab draw at a local facility
• Day 4 to 6: Lab results returned to the provider
• Day 6 to 7: Telehealth visit and e-prescription sent to pharmacy
• Day 7 to 10: Medication picked up or delivered

Total elapsed time ranges from 5 to 10 business days in most cases. If you have recent labs (within the past 3 to 6 months), many providers will accept those results and move directly to prescribing, compressing the timeline to 2 to 4 days.

Compounded formulations from 503A pharmacies may add 2 to 5 business days for preparation. Patients requiring a peanut-oil-free formulation should factor in this additional turnaround.

Safety Profile and Monitoring

OMP carries a favorable safety profile relative to synthetic progestins. The E3N French cohort study (N=80,377) found that micronized progesterone combined with estrogen was not associated with increased breast cancer risk over a mean 8.1-year follow-up, while synthetic progestins carried a relative risk of 1.69 (95% CI: 1.50 to 1.91).

Common side effects include drowsiness (reported by 8 to 15% of users), headache, bloating, and breast tenderness. These tend to diminish within the first 2 to 3 months.

Monitoring after initiation is straightforward. Most Florida providers schedule a follow-up at 3 months, then annually, with repeat labs including estradiol, progesterone, and liver function tests. Women on continuous combined HRT should report any unexpected vaginal bleeding promptly, as this may warrant endometrial evaluation.

OMP is contraindicated in women with active liver disease, known or suspected breast cancer, undiagnosed vaginal bleeding, or a history of blood clots related to hormone use per the FDA prescribing information.